Vikas Goel

Vikas Goel is an accomplished Executive Director in the field of biology, currently leading a multidisciplinary team at Zafrens since March 2023 to enhance drug discovery through ultra-high throughput phenotypic screening. Prior to this role, Vikas served as the Director of Cancer Biology and Translational Research at Turning Point Therapeutics, where oversight of a team and resource allocation contributed to significant advancements in cancer therapeutics. With extensive experience at eFFECTOR Therapeutics, including serving as Principal Scientist, Vikas was instrumental in the development of the MNK1/2 inhibitor currently evaluated in Phase II trials. Vikas's academic credentials include a Ph.D. in Molecular Microbiology and previous roles in research and academia at prestigious institutions.